全文获取类型
收费全文 | 5369篇 |
免费 | 584篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 197篇 |
妇产科学 | 121篇 |
基础医学 | 775篇 |
口腔科学 | 88篇 |
临床医学 | 629篇 |
内科学 | 953篇 |
皮肤病学 | 55篇 |
神经病学 | 446篇 |
特种医学 | 336篇 |
外科学 | 587篇 |
综合类 | 115篇 |
一般理论 | 9篇 |
预防医学 | 747篇 |
眼科学 | 94篇 |
药学 | 389篇 |
中国医学 | 15篇 |
肿瘤学 | 390篇 |
出版年
2021年 | 78篇 |
2020年 | 48篇 |
2019年 | 62篇 |
2018年 | 94篇 |
2017年 | 68篇 |
2016年 | 86篇 |
2015年 | 77篇 |
2014年 | 108篇 |
2013年 | 188篇 |
2012年 | 210篇 |
2011年 | 231篇 |
2010年 | 132篇 |
2009年 | 130篇 |
2008年 | 244篇 |
2007年 | 257篇 |
2006年 | 202篇 |
2005年 | 224篇 |
2004年 | 200篇 |
2003年 | 197篇 |
2002年 | 163篇 |
2001年 | 170篇 |
2000年 | 161篇 |
1999年 | 119篇 |
1998年 | 85篇 |
1997年 | 95篇 |
1996年 | 80篇 |
1995年 | 85篇 |
1994年 | 66篇 |
1993年 | 70篇 |
1992年 | 138篇 |
1991年 | 129篇 |
1990年 | 144篇 |
1989年 | 107篇 |
1988年 | 126篇 |
1987年 | 132篇 |
1986年 | 103篇 |
1985年 | 136篇 |
1984年 | 88篇 |
1983年 | 69篇 |
1982年 | 49篇 |
1981年 | 40篇 |
1980年 | 46篇 |
1979年 | 62篇 |
1978年 | 45篇 |
1976年 | 43篇 |
1975年 | 57篇 |
1974年 | 55篇 |
1973年 | 45篇 |
1971年 | 39篇 |
1970年 | 38篇 |
排序方式: 共有5982条查询结果,搜索用时 16 毫秒
11.
The 1990s are presenting new challenges to hospital CEOs. One theme currently emerging is the ethics of resource allocation. As they search for ways to fulfill their community responsibilities under pressures related to reimbursement, technology and community desires, hospitals are finding that they must make some very tough choices in how they allocate resources. Given the opportunity, how would you respond? Compare your response to an ethical scenario with those of three nationally recognized hospital CEOs. 相似文献
12.
13.
14.
15.
16.
Concentric sclerosis (Baló): Morphometric and in situ hybridization study of lesions in six patients
Da-Lin Yao Henry deF. Webster Lynn D. Hudson Michael Brenner Duo-San Liu Alfonso I. Escobar Samuel Komoly 《Annals of neurology》1994,35(1):18-30
Brain tissues from 6 patients with concentric sclerosis (Baló) were examined by in situ hybridization, immunocytochemistry, morphometry, and histological methods. The patients were 24 to 48 years old and had progressive cerebral symptoms and signs that lasted 15 to 100 days. Large demyelinative lesions, most frequent in the frontal white matter, contained alternating bands of demyelinated and partly myelinated white matter that were arranged in concentric or mosaic patterns. In the areas of demyelination, axons were relatively well preserved and there were perivascular inflammatory infiltrates. In 2 specimens, lesions contained regions with the characteristic appearance of actively demyelinating multiple sclerosis plaques. Oligodendroglial densities were highest in normal-appearing white matter, lower in partially myelinated areas, and lowest in demyelinated areas, which also contained many hypertrophic astrocytes closely associated with oligodendroglia. Messenger RNA levels for myelin-related proteins followed the same pattern; they were lowest in demyelinated areas, higher in partially myelinated areas, and highest in normal-appearing white matter beyond lesion margins. Our findings suggest that concentric sclerosis is a variant of multiple sclerosis, that oligodendroglial loss is important in the pathogenesis of demyelination, and that partially myelinated areas probably represent stages of ongoing myelin breakdown rather than remyelination of previously demyelinated areas. 相似文献
17.
MGC Hendriks P Dogterom JT Ebels B Oosterhuis LR Geertsema T Hulot G Bianchetti and JHG Jonkman 《Fundamental & clinical pharmacology》1998,12(5):559-565
Summary— In the present study we have compared the steady state biopharmaceutic characteristics of four diltiazem once daily controlled release capsules: Mono-Tildiem LP 300® (300 mg), Adizem® XL (300 mg)1, Cardizem® (300 mg) and Dilacor® (240 mg). Sixteen healthy male volunteers (aged 22.9 ± 3.3 years, range 19–31 years) completed an open label, multiple oral dose, randomized, four-period crossover study without a washout period in between. The volunteers received each diltiazem formulation once daily for four days. Trough diltiazem and metabolites plasma concentrations were determined on days 3 and 4. The 24-h plasma concentration-time profiles were assessed after the dose on day 4 of each period. The following steady state pharmacokinetic parameters for diltiazem were calculated: the minimum plasma concentration (cmin), the maximum plasma concentration (cmax), the time to reach that concentration (tmax), the time interval during which the plasma concentration exceeds 50% of cmax (t50), the area under the plasma concentration-time curve (AUC72–96) and the peak-to-trough fluctuation (PTF). For the metabolites of diltiazem, N-mono-desmethyl-diltiazem (NDM) and desacetyldiltiazem (DAD), AUC72–96 (AUCNDM and AUCDAD) and the ratio metabolite/parent compound were calculated. Steady state was achieved on day 3. Except one, all controlled release formulations have satisfactory controlled release properties allowing once daily administration. However, significant (P < 0.05) differences were found between the pharmacokinetic characteristics which do not allow exchange of the various formulations. Concentrations well below 50 ng·mL-1 in the morning hours were observed for Dilacor® (240 mg) and Adizem® XL (300 mg), which could be a disadvantage of these formulations as it is well-known that ischaemic events occur at a higher rate during that part of the day. The plasma concentration profiles of NDM and DAD, the major circulating metabolites, parallel the plasma concentration profiles for the parent compound. From a clinical point of view, all treatments were well tolerated. 相似文献
18.
19.
20.
The regulation of interleukin 6 (IL-6) expression in the B-lymphocyte-supporting murine stromal cell line BMS2 has been examined in response to exogenous cytokines and chemical agents. Kinetic analyses of IL-6 mRNA induction and decay are presented together with analysis of the IL-6 biological activity. The cytokines tumor necrosis factor, interleukin 1 (alpha and beta), and transforming growth factor beta, as well as forskolin and dibutyryl cyclic AMP, all induce a transient rise in the steady-state level of IL-6 mRNA and an increased release of IL-6 protein. To study its regulation at the chromatin level, the murine IL-6 genomic gene has been cloned. Induction of IL-6 expression correlates with increased DNA nicking, consistent with increased topoisomerase I and endogenous nuclease activity. This finding is supported by kinetic analyses using camptothecin, a topoisomerase I inhibitor. We conclude that IL-6 regulation in murine stromal cells capable of supporting B-lymphopoiesis is comparable to that observed in human diploid fibroblasts. 相似文献